Aller au contenu

Simon Couillard

Professeur, Faculté de médecine et des sciences de la santé

FMSS Département de médecine

Présentation

Sujet de recherche

Asthma, Cell Signaling and Infectious and Immune Diseases, Chronic Obstructive Pulmonary Disease, Immune Mediators: Cytokines and Chemokines

Disciplines de recherche

Immunology, Pneumology

Mots-clés

Asthma, Airway inflammation, Clinical prediction models, Chronic obstructive pulmonary disease (COPD)

Intérêts de recherche

Asthma of all severities: biomarkers, phenotypes, personalised medicine - specifically for clinical problems encountered by primary care providers. Airway inflammation: epithelial response, eosinophil biology. Clinical prediction modelling: prognostic modelling and prevention of asthma attacks. Chronic obstructive pulmonary disease (COPD): biomarkers, phenotypes, personalised medicine.

Centre de recherche

Centre de recherche du CHUS

Recherche clinique

Yes

Langues parlées et écrites

Anglais, Français

Diplômes

(2021). (Master's Thesis, MSc). University of Oxford.

(2021). (Research Associate, Clinical research fellowship). University of Oxford.

(2019). (Post-doctorate, Residency). Université de Sherbrooke.

(2017). (Certificate, Microprogram of 2nd cycle). Université de Sherbrooke.

(2017). (Post-doctorate, Residency). Université de Sherbrooke.

(2014). (Doctorate, MD). Université Laval.

Titres de compétence

Certificat de spécialiste (médecine interne) Specialist certificate (internal medicine). Collège des médecins du Québec.

Certificat de spécialiste (pneumologie) Specialist certificate (respirology). Collège des médecins du Québec.

FRCPC (médecine interne)(internal medicine). Royal College of Physicians and Surgeons of Canada (The).

FRCPC (pneumologie)(respirology). Royal College of Physicians and Surgeons of Canada (The).

Licentiate of the Medical Council of Canada. Medical Council of Canada.

Expérience académique

Assistant-professor in medicine. (2022-). Université de Sherbrooke. Canada.

Clinical research fellow; Area: severe asthma. (2019-2021). University of Oxford. United Kingdom.

Médecin résident (médecine interne puis pneumologie). (2014-2019). Université de Sherbrooke. Canada.

Stages de recherche clinique sous la supervision des Docteurs Jean-Louis Aubé et Pierre Larivée - 2 x 4 semaines Sujet : syndrome de chevauchement asthme sévère & apnée obstructive du sommeil. (2017-2018). Université de Sherbrooke. Canada.

Stage de recherche clinique sous la supervision des Docteurs Pierre Larivée et Alain Vanasse - 4 semaines Sujet : prédicteurs d’une réadmission pour exacerbation aigue de MPOC. (2016-2016). Université de Sherbrooke. Canada.

Stage de recherche clinique sous la supervision du Dr Louis-Philippe Boulet - 6 mois Sujet : santé respiratoire de l’athlète. (2011-2011). Université Laval. Canada.

Prix et distinctions

  • (2012) Tableau d’honneur académique canadien (Étudiant-athlète avec >80% moyenne générale). Sport interuniversitaire canadien. (Citation).
  • 11e position (hommes), Coupe du monde FINA * 32 km de nage en eau libre - 7h51min. Traversée internationale du Lac Saint-Jean. (Distinction).
  • 2018 ATS Abstract Scholarship. American Thoracic Society. (Prize / Award).
  • 2021 ATS Abstract Scholarship. American Thoraci Society. (Prize / Award).
  • BTS winter meeting conference grant. British Thoracic Society. (Prize / Award).
  • Bourse de finaliste national. Bourses Loran. (Prize / Award).
  • Boursier local. Bourses d’Excellence du Millénaire. (Prize / Award).
  • Graduated with Distinction from the University of Oxford MSc in Experimental and Translational Therapeutics. University of Oxford. (Distinction).
  • Meilleure qualité scientifique de l’exposé (Journée scientifique du département de médecine). Université de Sherbrooke. (Prize / Award).
  • Mention Honorable. Harvard National Model UN (simulation des nations unies). (Honor).
  • Reconnaissance de la FMRQ pour contribution remarquable au sein de ses instances. Fédération des médecins résidents du Québec (FMRQ). (Prize / Award).
  • Reconnaissance de l’implication étudiante. Université Laval. (Citation).
  • Étudiant athlète & service communautaire Lauréat national (SIC) & provincial (RSEQ) Natation. Sport interuniversitaire canadien. (Prize / Award).

Financement

  • Research Chair. (Awarded). Principal Investigator. Chaire de recherche en santé respiratoire de l’Association Pulmonaire du Québec (capitalised funds, interests for research). Canadian Lung Association (CLA). Chaire de recherche en santé respiratoire. 388 800 $. (2022-2027)
  • Grant. (Awarded). Principal Investigator. Phenotyping Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA): Clinical and Translational Correlation to Type-2 Inflammatory Biomarkers. Sanofi. Pathways Global Innovation Grant. 205 000 $. (2022-2024)
  • Grant. (Awarded). Principal Investigator. Quebec Respiratory Health Research Network - Career Start-Up and Mentorship Program for Young Investigators 2021-22. Fonds de recherche du Québec - Santé (FRQS). 25 000 $. (2022-2023)
  • Scholarship. (Awarded). Principal Investigator. Scholarship for clinical research fellowship in asthma. Société des Médecins (Sherbrooke, QC). 150 000 $. (2019-2022)
  • Grant. (Completed). Principal Investigator. Type 2 Innovation Grant- Mechanisms of FeNO non-suppression. Sanofi. Type 2 Innovation Grant. 80 000 $. (2019-2021)

Publications

Articles de revue

  • Khalfaoui L; Symon FA; Couillard S; Hargadon B; Chaudhuri R; Bicknell S; Mansur AH; Shrimanker R; Hinks TSC: Pavord ID; Fowler S; Brown V; McGarvey LP; Heaney LG; Austin CD; Howarth PH; Arron JR; Bradding P. (2022). Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma. Allergy DOI. (Published).
  • Corrisingham I, Richardson R, Hinks TSC, Spencer S, Couillard S, Maynard-Paquette AC, Howell I, Thomassen D. (2022). Biologics for chronic severe asthma: a network meta-analysis. Cochrane Database of Systematic Reviews (Revision Requested).
  • Couillard S, Steyerberg EW, Beasley R, Pavord ID. (2022). Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. BMJ Open 12 (4), DOI. (Published).
  • Couillard S; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC; Pavord ID. (2022). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax 77 (2), 199-202. DOI. (Published).
  • Couillard S Pavord ID. (2022). Fluticasone furoate: CAPTAIN of fluticasones in type-2 inflammatory asthma. Respirology 27 (3), 184-186. DOI. (Published).
  • Couillard S; Shrimanker R; Lemaire-Paquette S; Hynes GM; Borg C; Connolly C; Thulborn S; Moran AM; Poole S; Morgan S; Powell T; Pavord ID; Hinks TSC. (2022). Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. Thorax DOI. (Published).
  • Couillard S, Do W, Beasley R, Hinks TSC, Pavord ID. (2022). Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE). ERJ Open Research 8 (1), DOI. (Published).
  • Couillard S Pavord ID Heaney LG Petousi N Hinks TSC. (2022). Sub-stratification oftype-2 high airway disease for therapeutic decision-making: a ‘bomb’ (bloodeosinophils) meets ‘magnet’ (FeNO) framework. Respirology 27 (8), 573-477. DOI. (Published).
  • St-Germain O Lachapelle P Pavord ID Couillard S. (2022). Tackling ‘people remodelling’ in corticosteroid dependent asthma with type-2 targeting biologics and a formal corticosteroid weaning protocol. touchREVIEWS in Respiratory & Pulmonary Diseases (Submitted).
  • Couillard, S. (2022). The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence. European Respiratory Journal DOI. (Published).
  • Ramakrishnan S; Couillard S. (2021). Antibiotics for asthma attacks – masking uncertainty. European Respiratory Journal 58 (1), DOI. (Published).
  • Couillard S; Connolly C; Borg C; Pavord ID. (2021). Asthma in pregnancy: An update. Obstetric Medicine 14 (3), 135-144. DOI. (Published).
  • Couillard S; Shrimanker R; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord ID; Hinks TSC. (2021). Fractional Exhaled Nonsuppression Identifies Corticosteroid-Resistant Type-2 Signaling in SevereAsthma. Am J Respir Crit Care Med 204 (6), 731-734. DOI. (Published).
  • Couillard S; Jackson DJ; Wechsler M; Pavord ID. (2021). How I do it. Work-up of severe asthma. Chest 160 (6), 2019-2029. DOI. (Published).
  • Turnbull CD Porter BML Evans SB Smith O Lardner R Hallifax R Bettinson HV Talbot NP Bafadhel M Rahman NM Petousi N Achaiah A Addala D Banka R Bedawi E Chapman S Danbury H Couillard S Douglas E Elder P Fries A Flight W Fraser E Hardinge M Hinks TSC Ho LP Hoyles R Melhorn J Moore A Nathwani V Nickol A Park J Patel S Pavord ID Saunders P Laurenson-Schafer H Roxburgh F Sundaralingam A Sykes A Tsakok M Wilson R Wrightson JM. (2021). Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ Open Respiratory Research 8 (1), DOI. (Published).
  • Couillard S; Boulet LP; Lachapelle P. (2021). The controversial role of as-needed short-acting β2-agonist monotherapy in mild asthma: a short review of current guidelines. Can J of Resp Crit Care and Sleep Medicine 5 (5), 273-275. DOI. (Published).
  • Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimaki L. (2020). Blood Eosinophil Depletion with Mepolizumab, Benralizumab and Prednisolone in Eosinophilic Asthma. Am J Respir Crit Care Med 202 (9), 1314-1316. DOI. (Published).
  • Vanasse A; Courteau J; Courteau M; Benigeri M; Chiu YM; Dufour I; Couillard S; Larivée P; Hudon C. (2020). Healthcare utilization after a first hospitalization for COPD: a new approach of State Sequence Analysis based on the '6W' multidimensional model of care trajectories. BMC Health Serv Res 20 (1), 177. DOI. (Published).
  • Moran AM; Ramakrishnan S; Borg CA; Connolly CM; Couillard S; Mwasuku CM; Pavord ID; Hinks TSC; Lehtimӓki L. (2020). Reply to Lipworth et al.: Don't Forget about Facilitatory Effects of Corticosteroids on β 2-Adrenoceptors in Acute Asthma. Am J Respir Crit Care Med 202 (12), 1743-1744. DOI. (Published).
  • Qing L; Larivée P; Courteau J; Couillard S; Poder TG; Carrier N; Bélanger M; Vanasse A. (2019). Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths. Int J Chron Obstruct Pulmon Dis 2019 (14), 331-341. DOI. (Published).
  • Couillard S; Bélanger M; Bouchard N. (2019). Q fever presenting as miliary pneumonia: Case imagery and differential diagnosis. Can J of Resp Crit Care and Sleep Medicine 3 (3), 164-165. DOI. (Published).
  • Poder TG; Carrier N; Bélanger M; Couillard S; Courteau, J; Larivée, P; Vanasse A. (2018). Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec. Int J Chron Obstruct Pulmon Dis 8 (13), 3065-3076. DOI. (Published).
  • Bélanger M; Couillard S; Courteau J; Larivée P; Poder TG; Carrier N; Girard K; Vézina FA; Vanasse A. (2018). Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Int J Chron Obstruct Pulmon Dis 2018 (13), 3045-3054. DOI. (Published).
  • Couillard S; Larivée P; Courteau J; Vanasse A. (2017). Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions. Chest 151 (2), 366-373. DOI. (Published).
  • Vanasse A, Courteau J, Couillard S, Beauchesne MF, Larivée P. (2017). Predicting One-year Mortality After a “First” Hospitalization for Chronic Obstructive Pulmonary Disease: An Eight-Variable Assessment Score Tool. Journal of COPD 14 (5), 490-497. DOI. (Published).
  • Couillard, S; Bougault, V; Turmel, J; Boulet, LP. (2014). Perception of bronchoconstriction following methacholine and eucapnic voluntary hyperpnea challenges in elite athletes. Chest 145 (4), 794-802. DOI. (Published).

Chapitres de livre

  • Couillard S; Pavord I. (2022). Biological Therapies for Asthma. Encyclopedia of Respiratory Medicine (2). Elsevier. DOI. (In Press).

Articles de magazine

  • Selina Wellbelove. (2022). Targeting the ‘bomb’ or the ‘magnet’: a new therapeuticframework for asthma?. The Limbic Respiratory.

Rapports

  • Couillard S, Tanguay-Rioux X, Grandjean-Blanchet C, Dufour S, Labossière M, Ruel-Laliberté J. (2018). The Impact of Competence by Design (CBD): Report on semi-structured interviews conducted on the 2017-2018 cohort of R1s in anesthesiology and Otolaryngology/Head and Neck Surgery in Quebec.

Articles de conférence

  • Do W; Beasley R; Hinks TSC; Pavord ID; Couillard S. (2022). Development of a Prototype ORACLE Web-app to Predict Treatment Benefits of Type-2 Targeted Anti-inflammatory Treatment in Asthma. American Thoracic Society meeting. (Accepted).
  • Couillard S; Peterson S; Bengtson T; van den Berge M; Price D; Beasley R; Sadatsafavi M; Janson C; Belton L; Fageras M; Mullerova H; Pavord ID. (2022). Prototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates. American Thoracic Society meeting. (Accepted).
  • Couillard, S; Peterson, S; Bengtsson, T; van den Berge, M; Price, D; Beasley, R; Sadatsafavi, M; Janson, C; Papi, Alberto; Belton, L; Fagerås, M; Müllerová, H; Pavord, I. (2022). Risk factors for corticosteroid- and antibiotic only-treated asthma attacks in the NOVELTY cohort. European Respiratory Society congress. (Submitted).
  • Couillard S; Laugerud A; Jabeen M; Ramakrishnan S; Melorn J; Hinks T; Pavord I. (2021). A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk scaLE (ORACLE). American Thoracic Society meeting. (Published).
  • Couillard S; Beasley R; Steyerberg EW; Pavord ID. (2021). Blood eosinophils, exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S; Melhorn J; Singhania A; Horowitz D; Djukanovic C; Woelk CH; Hinks TSC. (2021). Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma. European Respiratory Society congress. (Published).
  • Couillard, S; Melhorn J; Singhania A; Horowitz D; Djukanovic R; Woelk CH; Hinks TSC. (2021). Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma. British Thoracic Society winter meeting. (Published).
  • Couillard S; Melhorn J; Singhania A; Horowitz D; Djukanovíc R; Woelk C; Hinks TSC. (2021). Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S; Laugerud A; Jabeen M; Ramakrishnan R; Melhorn J; Hinks TSC; Pavord ID. (2021). Derivation of a prototype asthmaattack risk scale centred on blood eosinophils and exhaled nitric oxide. Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC: Pavord ID. (2021). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. British Thoracic Society winter meeting. (Published).
  • Couillard S; Shrimanker R; Hynes G; Connolly C: Hayman A; Thulborn S; Poole S; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord I; Hinks TSC. (2021). FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma. British Thoracic Society winter meeting. (Published).
  • Couillard S; Shrimanker R; Hynes G; Connolly C; Haryman A; Thulborn S; Moran A; Poole S; Powell T; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler S; Bradding P; Pavord ID; Hinks TSC. (2021). Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. Journées Québécoises de Recherche en Santé Respiratoire. (Accepted).
  • Couillard S; Do W; Beasley R; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC; Pavord ID. (2021). Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE). Journées Québécoises de Recherche en Santé Respiratoire. (Published).
  • Couillard S; Shrimanker R; Hynes G; Borg C; Connolly C; Hayman A; Thulborn S; Moran A; Poole S; Powell T; Chaudhuri R; Mansur AH; McGarvey LP; Heaney LG; Fowler SJ; Bradding P; Pavord ID; Hinks TSC. (2021). Raised FeNO in optimally-treated severe asthma identifies persistent eosinophilic chemotactic pull towards the airway. European Respiratory Society congress. (Published).
  • Couillard S; Do W; Beasley R; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks TSC; Pavord ID. (2021). To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments. British Thoracic Society winter meeting. (Published).
  • Oliver ME; Poole S; Borg C; Connolly C; Pavord ID; Hinks TSC; Couillard S. (2021). Utility of adherence checks in patients with severe asthma eligible for biologics: a single centreretrospective analysis. European Respiratory Society congress. (Published).
  • Oliver M.E.; Poole S; Borg C; Connolly C; Pavord ID; Hinks TSC: Couillard S. (2021). Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis. British Thoracic Society winter meeting. (Published).
  • Dupras-Boileaum C; Couillard S; Gaudette E; Poulin Y. (2020). A Case of Follicular Lymphoma Presenting as Severe Interstitial Pneumonia. American Thoracic Society meeting. (Published).
  • Couillard S; Shrimanker R; Hynes G; Borg C; Connolly C; Harman A; Poole S; Moran A; Powell T; Pavord I; Hinks T. (2020). Mechanisms of FeNO Non-Suppression in Severe Asthma: Analysis of Sputum Type 2 Cytokines and Chemokines. European Respiratory Society congress. (Published).
  • Bélanger M; Couillard S; Vézina FA; Girard K; Larivée P; Poder TG; Courteau J; Vanasse A. (2018). Blood Eosinophil levels in First Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Are Associated with Increased COPD-Related Readmissions. American Thoracic Society meeting. (Published).
  • Couillard S; Bélanger M; Courteau J; Larivée P; Vanasse A. (2018). Blood eosinophils, readmissions and healthcare costs in COPD: a retrospective analysis. AstraZeneca Scientific Summit – Respiratory medicine. (Published).
  • Couillard S; Bélanger M; Bouchard N. (2018). Miliary pneumonia asa novel radiological manifestation of Q fever. American Thoracic Society meeting. (Published).
  • Tanguay-Rioux X; Grandjean-Blanchet C; Dufour S; Labossière M; Ruel-Laliberté J; Couillard S. (2018). The Impact of Competency by Design. Canadian Conference on Medical Education. (Published).
  • Tanguay-Rioux X; Grandjean-Blanchet C; Dufour S; Labossière M; Ruel-Laliberté J; Couillard S. (2018). The Impact of Competency by Design. International Conference on Residency Education. (Published).

Autres contributions

Cours enseignés

  • Applied Respiratory Pathophysiology. (2020-02-10 à 2021-02-10).(3CR).

Activités de collaboration internationale

  • Co-investigator. United Kingdom. Biomarker-stratified asthma exacerbation rates in the NOVELTY prospectiveobservational cohort and validation of the prototype Oxford Asthma attaCk risk scaLE (ORACLE).
  • Lead investigator. United Kingdom. Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: systemic review and control arm patient-level meta-analysis for clinical prediction modelling.

Présentations

  • Couillard S, Pavord I. (2022). Blood eosinophils, FeNO, and the modifiable risk of asthma attacks. AstraZeneca National Speaker Tour. Calgary, Canada
  • Couillard S. (2022). Measuring eosinophilic airway inflammation. TADIS 2022: Treatable Traits Initiative. United Kingdom
  • Couillard S. (2022). The OxfoRd Asthma attaCk risk scaLE (ORACLE). GSK UK Scientific Workshop: Biomarkers in Severe Asthma. Londres, United Kingdom
  • Couillard S. (2022). The OxfoRd Asthma attaCk risk scaLE (ORACLE) papers. Centre of Excellence in Treatable Traits Journal Club. Newcastle, Australia
  • Couillard S, Pavord I. (2022). Type-2 inflammation as a treatable trait. Treatable Trait Symposium. Helsinki, Finland
  • Pavord I, Hinks T, Couillard S. (2022). Work-up of severe asthma. Oxford Masterclass on Difficult Asthma. Oxford, United Kingdom
  • Couillard S. (2021). Blood eosinophils, FeNO, and the modifiable risk of asthma attacks. Grupo de Rasgos Tratables y Medicini de Precisión. Bogota, Colombia
  • Côté A, Couillard S. (2021). Débat sur l’utilisation des biomarqueurs dans la prise en charge de l’asthme sévère. Forum québécois d'échanges scientifiques en santé respiratoire. Sherbrooke, Canada
  • Couillard S. (2021). L’investigation de l’asthme sévère. Congrès annuel de l'APPQ. Sherbrooke, Canada
  • Pavord I, Russell R, Hinks T, Couillard S. (2021). Work-up of severe asthma. Oxford Masterclass on Difficult Asthma. Oxford, United Kingdom
  • Pavord I, Bafadhel M, Hinks TSC, Russell R, Couillard S. (2021). Work-up of severe asthma. Optimising the Management of Severe Asthma. Oxford, United Kingdom
  • Pavord I, Couillard S. (2019). Grand Rounds clinical case: aspirin exacerbated respiratory disease. Oxford Grand Rounds, Acute General Medicine. Sherbrooke, United Kingdom